Authors:
Kurinchi Selvan Gurusamy, David Moher, David Moher, Marilena Loizidou, Irfan Ahmed, Marc T. Avey, Marc T. Avey, Carly C. Barron, Carly C. Barron, Carly C. Barron, Brian R. Davidson, Miriam Dwek, Christian Gluud, Gavin Jell, Kiran Kumar Katakam, Joshu (...)
Kurinchi Selvan Gurusamy, David Moher, David Moher, Marilena Loizidou, Irfan Ahmed, Marc T. Avey, Marc T. Avey, Carly C. Barron, Carly C. Barron, Carly C. Barron, Brian R. Davidson, Miriam Dwek, Christian Gluud, Gavin Jell, Kiran Kumar Katakam, Joshua Montroy, Timothy D. McHugh, Nicola J. Osborne, Merel Ritskes-Hoitinga, Kees van Laarhoven, Jan Vollert, Jan Vollert, Manoj M. Lalu
(Read More)
Abstract:
Background Only a small proportion of preclinical research (research performed in animal models prior to clinical trials in humans) translates into clinical benefit in humans. Possible reasons for the lack of translation of the results observed in preclinical research into human clinical benefit include the design, conduct, and reporting of preclinical studies. There is currently no formal domain-based assessment of the clinical relevance of preclinical research. To address this issue, we have develop (...)
Background Only a small proportion of preclinical research (research performed in animal models prior to clinical trials in humans) translates into clinical benefit in humans. Possible reasons for the lack of translation of the results observed in preclinical research into human clinical benefit include the design, conduct, and reporting of preclinical studies. There is currently no formal domain-based assessment of the clinical relevance of preclinical research. To address this issue, we have developed a tool for the assessment of the clinical relevance of preclinical studies, with the intention of assessing the likelihood that therapeutic preclinical findings can be translated into improvement in the management of human diseases. Methods We searched the EQUATOR network for guidelines that describe the design, conduct, and reporting of preclinical research. We searched the references of these guidelines to identify further relevant publications and developed a set of domains and signalling questions. We then conducted a modified Delphi-consensus to refine and develop the tool. The Delphi panel members included specialists in evidence-based (preclinical) medicine specialists, methodologists, preclinical animal researchers, a veterinarian, and clinical researchers. A total of 20 Delphi-panel members completed the first round and 17 members from five countries completed all three rounds. Results This tool has eight domains (construct validity, external validity, risk of bias, experimental design and data analysis plan, reproducibility and replicability of methods and results in the same model, research integrity, and research transparency) and a total of 28 signalling questions and provides a framework for researchers, journal editors, grant funders, and regulatory authorities to assess the potential clinical relevance of preclinical animal research. Conclusion We have developed a tool to assess the clinical relevance of preclinical studies. This tool is currently being piloted.
(Read More)